Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.
Journal
Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
01
12
2023
accepted:
10
04
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Single-nucleotide variants (SNVs) in key T cell genes can drive clinical pathologies and could be repurposed to improve cellular cancer immunotherapies. Here, we perform massively parallel base-editing screens to generate thousands of variants at gene loci annotated with known or potential clinical relevance. We discover a broad landscape of putative gain-of-function (GOF) and loss-of-function (LOF) mutations, including in PIK3CD and the gene encoding its regulatory subunit, PIK3R1, LCK, SOS1, AKT1 and RHOA. Base editing of PIK3CD and PIK3R1 variants in T cells with an engineered T cell receptor specific to a melanoma epitope or in different generations of CD19 chimeric antigen receptor (CAR) T cells demonstrates that discovered GOF variants, but not LOF or silent mutation controls, enhanced signaling, cytokine production and lysis of cognate melanoma and leukemia cell models, respectively. Additionally, we show that generations of CD19 CAR T cells engineered with PIK3CD GOF mutations demonstrate enhanced antigen-specific signaling, cytokine production and leukemia cell killing, including when benchmarked against other recent strategies.
Identifiants
pubmed: 38783148
doi: 10.1038/s41587-024-02235-x
pii: 10.1038/s41587-024-02235-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678–689 (2022).
pubmed: 35440724
pmcid: 9305718
doi: 10.1038/s41591-022-01765-8
Forget, M.-A. et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin. Cancer Res. 24, 4416–4428 (2018).
pubmed: 29848573
pmcid: 6139043
doi: 10.1158/1078-0432.CCR-17-3649
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
pubmed: 25838374
pmcid: 6295668
doi: 10.1126/science.aaa4967
Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat. Rev. Drug Discov. 22, 976–995 (2023).
Ho, P. et al. The CD58–CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell 41, 1207–1221 (2023).
pubmed: 37327789
doi: 10.1016/j.ccell.2023.05.014
Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328–1334 (2020).
pubmed: 33303615
pmcid: 8883579
doi: 10.1126/science.abb9847
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
pubmed: 33020644
pmcid: 8446909
doi: 10.1038/s41591-020-1061-7
Anderson, N. D. et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat. Med. 29, 1700–1709 (2023).
pubmed: 37407840
pmcid: 10353931
doi: 10.1038/s41591-023-02415-3
McGuirk, J. et al. A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR–Cas9-engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON). J. Clin. Oncol. 39, TPS7570 (2021).
Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958–1971 (2018).
pubmed: 30449619
pmcid: 6689405
doi: 10.1016/j.cell.2018.10.024
Dai, X. et al. Massively parallel knock-in engineering of human T cells. Nat. Biotechnol. 41, 1239–1255 (2023).
pubmed: 36702900
doi: 10.1038/s41587-022-01639-x
Li, B. et al. Cis interactions between CD2 and its ligands on T cells are required for T cell activation. Sci. Immunol. 7, eabn6373 (2022).
pubmed: 35930657
doi: 10.1126/sciimmunol.abn6373
Dubrot, J. et al. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity 54, 571–585 (2021).
pubmed: 33497609
doi: 10.1016/j.immuni.2021.01.001
Nahmad, A. D. et al. Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage. Nat. Biotechnol. 40, 1807–1813 (2022).
pubmed: 35773341
pmcid: 7613940
doi: 10.1038/s41587-022-01377-0
Patel, C. H. et al. TSC2 S1365A mutation potently regulates CD8
Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317–1319 (2005).
pubmed: 16273109
doi: 10.1038/ng1673
Pawlak-Adamska, E. et al. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease. Endocrine 55, 186–199 (2017).
pubmed: 27638540
doi: 10.1007/s12020-016-1096-1
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).
pubmed: 32572269
doi: 10.1038/s41587-020-0561-9
Webber, B. R. et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat. Commun. 10, 5222 (2019).
pubmed: 31745080
pmcid: 6864045
doi: 10.1038/s41467-019-13007-6
Kluesner, M. G. et al. CRISPR–Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nat. Commun. 12, 2437 (2021).
pubmed: 33893286
pmcid: 8065034
doi: 10.1038/s41467-021-22009-2
Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892–900 (2020).
pubmed: 32284586
doi: 10.1038/s41587-020-0491-6
Diorio, C. et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 140, 619–629 (2022).
pubmed: 35560156
pmcid: 9373016
doi: 10.1182/blood.2022015825
Glaser, V. et al. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells. Genome Biol. 24, 89 (2023).
pubmed: 37095570
pmcid: 10123993
doi: 10.1186/s13059-023-02928-7
Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97–110 (2020).
pubmed: 31937940
pmcid: 6980783
doi: 10.1038/s41551-019-0501-5
Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883–891 (2020).
pubmed: 32433547
pmcid: 7357821
doi: 10.1038/s41587-020-0453-z
Woodruff, R. et al. Large-scale manufacturing of base-edited chimeric antigen receptor T cells. Mol. Ther. Methods Clin. Dev. 31, 101123 (2023).
pubmed: 37886606
pmcid: 10597784
doi: 10.1016/j.omtm.2023.101123
Martin-Rufino, J. D. et al. Massively parallel base editing to map variant effects in human hematopoiesis. Cell 186, 2456–2474 (2023).
pubmed: 37137305
doi: 10.1016/j.cell.2023.03.035
Kim, E. & Hart, T. Improved analysis of CRISPR fitness screens and reduced off-target effects with the BAGEL2 gene essentiality classifier. Genome Med. 13, 2 (2021).
pubmed: 33407829
pmcid: 7789424
doi: 10.1186/s13073-020-00809-3
Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).
pubmed: 35113687
pmcid: 9307090
doi: 10.1126/science.abj4008
Schmidt, R. et al. Base-editing mutagenesis maps alleles to tune human T cell functions. Nature 625, 805–812 (2024).
pubmed: 38093011
doi: 10.1038/s41586-023-06835-6
Zimmermann, M. et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 559, 285–289 (2018).
pubmed: 29973717
pmcid: 6071917
doi: 10.1038/s41586-018-0291-z
Ramezani, M. et al. A genome-wide atlas of human cell morphology. Preprint at bioRxiv https://doi.org/10.1101/2023.08.06.552164 (2023).
Legut, M. et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603, 728–735 (2022).
pubmed: 35296855
pmcid: 9908437
doi: 10.1038/s41586-022-04494-7
Jaitin, D. A. et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-seq. Cell 167, 1883–1896 (2016).
pubmed: 27984734
doi: 10.1016/j.cell.2016.11.039
Han, K. et al. CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature 580, 136–141 (2020).
pubmed: 32238925
pmcid: 7368463
doi: 10.1038/s41586-020-2099-x
Cooper, S. E. et al. scSNV-seq: high-throughput phenotyping of single nucleotide variants by coupled single-cell genotyping and transcriptomics. Genome Biol. 25, 20 (2024).
pubmed: 38225637
pmcid: 10789043
doi: 10.1186/s13059-024-03169-y
Coelho, M. A. et al. Base editing screens map mutations affecting interferon-γ signaling in cancer. Cancer Cell 41, 288–303 (2023).
pubmed: 36669486
pmcid: 9942875
doi: 10.1016/j.ccell.2022.12.009
Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174–182 (2022).
pubmed: 36002574
pmcid: 9433322
doi: 10.1038/s41586-022-05126-w
Belk, J. A. et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768–786 (2022).
pubmed: 35750052
pmcid: 9949532
doi: 10.1016/j.ccell.2022.06.001
Puck, J. M. et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood 89, 1968–1977 (1997).
pubmed: 9058718
Gureasko, J. et al. Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc. Natl Acad. Sci. USA 107, 3430–3435 (2010).
pubmed: 20133692
pmcid: 2816639
doi: 10.1073/pnas.0913915107
Yi, K. H. & Lauring, J. Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget 7, 4241–4251 (2015).
pmcid: 4826202
doi: 10.18632/oncotarget.6648
Shimizu, H., Toma-Fukai, S., Kontani, K., Katada, T. & Shimizu, T. GEF mechanism revealed by the structure of SmgGDS-558 and farnesylated RhoA complex and its implication for a chaperone mechanism. Proc. Natl Acad. Sci. USA 115, 9563–9568 (2018).
pubmed: 30190425
pmcid: 6156624
doi: 10.1073/pnas.1804740115
Andersson, E. et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 30, 1204–1208 (2016).
pubmed: 26419508
doi: 10.1038/leu.2015.263
Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195–203 (2012).
pubmed: 22358332
doi: 10.1038/nrm3290
Cheung, L. W. et al. Regulation of the PI3K pathway through a p85α monomer–homodimer equilibrium. eLife 4, e06866 (2015).
pubmed: 26222500
pmcid: 4518712
doi: 10.7554/eLife.06866
Dornan, G. L. & Burke, J. E. Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class IA phosphoinositide 3-kinases. Front. Immunol. 9, 575 (2018).
pubmed: 29616047
pmcid: 5868324
doi: 10.3389/fimmu.2018.00575
Zhao, P. et al. Activated phosphoinositide 3-kinase delta syndrome caused by PIK3CD mutations: expanding the phenotype. Pediatr. Rheumatol. Online J. 22, 24 (2024).
pubmed: 38287413
pmcid: 10823743
doi: 10.1186/s12969-024-00955-7
Courtney, A. H. et al. A phosphosite within the SH2 domain of Lck regulates its activation by CD45. Mol. Cell 67, 498–511 (2017).
pubmed: 28735895
pmcid: 5558854
doi: 10.1016/j.molcel.2017.06.024
Yamaguchi, H. & Hendrickson, W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384, 484–489 (1996).
pubmed: 8945479
doi: 10.1038/384484a0
Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388–2407 (2023).
pubmed: 37776850
doi: 10.1016/j.immuni.2023.09.001
Zhang, X. et al. Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. J. Int. Med. Res. 49, 03000605211013222 (2021).
pubmed: 34039074
pmcid: 8755648
Neugebauer, M. E. et al. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat. Biotechnol. 41, 673–685 (2023).
pubmed: 36357719
doi: 10.1038/s41587-022-01533-6
Cuella-Martin, R. et al. Functional interrogation of DNA damage response variants with base editing screens. Cell 184, 1081–1097 (2021).
pubmed: 33606978
pmcid: 8018281
doi: 10.1016/j.cell.2021.01.041
Wang, Y., Huang, H., Rudin, C. & Shaposhnik, Y. Understanding how dimension reduction tools work: an empirical approach to deciphering t-SNE, UMAP, TriMap, and PaCMAP for data visualization. J. Mach. Learn. Res. 22, 1–73 (2021).
Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014).
pubmed: 24463181
pmcid: 4016707
doi: 10.1093/bioinformatics/btu048
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR–Cas9. Nat. Biotechnol. 34, 184–191 (2016).
pubmed: 26780180
pmcid: 4744125
doi: 10.1038/nbt.3437
Hanna, R. E. et al. Massively parallel assessment of human variants with base editor screens. Cell 184, 1064–1080 (2021).
pubmed: 33606977
doi: 10.1016/j.cell.2021.01.012
Szklarczyk, D. et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646 (2023).
pubmed: 36370105
doi: 10.1093/nar/gkac1000
Frangieh, C. J. et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat. Genet. 53, 332–341 (2021).
pubmed: 33649592
pmcid: 8376399
doi: 10.1038/s41588-021-00779-1
Wang, T., Lander, E. S. & Sabatini, D. M. Single guide RNA library design and construction. Cold Spring Harb. Protoc. 2016, pdb.prot090803 (2016).
pubmed: 26933249
pmcid: 4804709
doi: 10.1101/pdb.prot090803
McKinney, W. Data structures for statistical computing in Python. In Proceedings of the 9th Python in Science Conference (eds van der Walt, S. & Millman, J.) 56–61 (SciPy, 2010).
Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261–272 (2020).
pubmed: 32015543
pmcid: 7056644
doi: 10.1038/s41592-019-0686-2
Waskom, M. L. seaborn: statistical data visualization. J. Open Source Softw. 6, 3021 (2021).
doi: 10.21105/joss.03021
Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90–95 (2007).
doi: 10.1109/MCSE.2007.55
Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 554 (2014).
pubmed: 25476604
pmcid: 4290824
doi: 10.1186/s13059-014-0554-4
Zhang, J., Pei, J., Durham, J., Bos, T. & Cong, Q. Computed cancer interactome explains the effects of somatic mutations in cancers. Protein Sci. 31, 1–19 (2022).
doi: 10.1002/pro.4479
The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45, D158–D169 (2017).
doi: 10.1093/nar/gkw1099
Kluesner, M. G. et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239–250 (2018).
pubmed: 31021262
pmcid: 6694769
doi: 10.1089/crispr.2018.0014
Nuñez Pedrozo, C. N. et al. In silico performance analysis of web tools for CRISPRa sgRNA design in human genes. Comput. Struct. Biotechnol. J. 20, 3779–3782 (2022).
pubmed: 35891794
pmcid: 9304428
doi: 10.1016/j.csbj.2022.07.023
Nguyen, D. N. et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat. Biotechnol. 38, 44–49 (2020).
pubmed: 31819258
doi: 10.1038/s41587-019-0325-6
Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405–409 (2018).
pubmed: 29995861
pmcid: 6239417
doi: 10.1038/s41586-018-0326-5
Walsh, Z. H. et al. Mapping variant effects on anti-tumor hallmarks of primary human T cells with base editing screens. Source code. GitHub github.com/gnikolenyi/izar_vis (2024).